Bank of New York Mellon Corp Purchases 5,406 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Share on StockTwits

Bank of New York Mellon Corp lifted its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 7.7% during the 2nd quarter, Holdings Channel reports. The firm owned 75,353 shares of the biotechnology company’s stock after acquiring an additional 5,406 shares during the period. Bank of New York Mellon Corp’s holdings in Aldeyra Therapeutics were worth $452,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Strs Ohio grew its holdings in shares of Aldeyra Therapeutics by 7.5% in the second quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 5,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Aldeyra Therapeutics by 16.8% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 95,859 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 13,775 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of Aldeyra Therapeutics by 12.1% in the second quarter. Mesirow Financial Investment Management Inc. now owns 62,736 shares of the biotechnology company’s stock worth $373,000 after purchasing an additional 6,775 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Aldeyra Therapeutics by 47.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 61,536 shares of the biotechnology company’s stock worth $370,000 after purchasing an additional 19,826 shares during the last quarter. Finally, Private Advisors LLC grew its holdings in shares of Aldeyra Therapeutics by 21.8% in the second quarter. Private Advisors LLC now owns 40,270 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 7,211 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

Several research analysts have recently issued reports on ALDX shares. Cantor Fitzgerald set a $33.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 25th. ValuEngine upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 10th. Finally, Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aldeyra Therapeutics currently has a consensus rating of “Buy” and an average price target of $24.19.

In related news, CEO Todd C. Brady purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were acquired at an average price of $4.89 per share, for a total transaction of $48,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately $244,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Todd C. Brady purchased 14,288 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was bought at an average price of $5.91 per share, for a total transaction of $84,442.08. Following the acquisition, the chief executive officer now owns 614,826 shares of the company’s stock, valued at $3,633,621.66. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 83,907 shares of company stock worth $456,912. 13.50% of the stock is currently owned by company insiders.

Shares of Aldeyra Therapeutics stock opened at $5.15 on Tuesday. Aldeyra Therapeutics, Inc has a 52-week low of $4.31 and a 52-week high of $13.32. The stock has a market capitalization of $144.79 million, a price-to-earnings ratio of -2.88 and a beta of 0.86. The company’s 50 day moving average price is $5.29 and its 200-day moving average price is $6.42.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.02. Analysts forecast that Aldeyra Therapeutics, Inc will post -2.01 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Recommended Story: How to invest in a bear market

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.